WO2017055324A1 - Procédés de quantification de la population de cellules d'origine monocytaire dans un prélèvement de tissu - Google Patents

Procédés de quantification de la population de cellules d'origine monocytaire dans un prélèvement de tissu Download PDF

Info

Publication number
WO2017055324A1
WO2017055324A1 PCT/EP2016/073055 EP2016073055W WO2017055324A1 WO 2017055324 A1 WO2017055324 A1 WO 2017055324A1 EP 2016073055 W EP2016073055 W EP 2016073055W WO 2017055324 A1 WO2017055324 A1 WO 2017055324A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
cells
cell
gene
mcp
Prior art date
Application number
PCT/EP2016/073055
Other languages
English (en)
Inventor
Wolf Herman Fridman
Aurélien De Reynies
Etienne BECHT
Original Assignee
INSERM (Institut National de la Santé et de la Recherche Médicale)
Université Paris Diderot - Paris 7
Université Pierre Et Marie Curie (Paris 6)
Université Paris Descartes
Ligue Nationale Contre Le Cancer
Assistance Publique-Hôpitaux De Paris (Aphp)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paris Diderot - Paris 7, Université Pierre Et Marie Curie (Paris 6), Université Paris Descartes, Ligue Nationale Contre Le Cancer, Assistance Publique-Hôpitaux De Paris (Aphp) filed Critical INSERM (Institut National de la Santé et de la Recherche Médicale)
Publication of WO2017055324A1 publication Critical patent/WO2017055324A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • the present invention relates to methods for quantifying the population of cells of monocytic origin in a tissue sample.
  • the composition of the tumor microenvironment is of paramount importance during tumor development.
  • infiltration by cells of the adaptive immune system helps control tumor growth and correlate with a favorable clinical outcome in most cancers.
  • a consensual result is that infiltration with memory CD8+ T cells is associated with a favorable patient's outcome.
  • clear cell renal cell carcinoma (ccRCC) where angiogenesis is highly due to mutations disrupting the HIF pathway regulating the cellular response to hypoxia, tumor-infiltration by CD8+ T cells is associated with a poor prognosis for the patient.
  • CD 8+ T cells infiltration is associated with a strong infiltration by other immune cells, including B cells and cells of monocytic origin.
  • CRC colorectal cancer
  • the subgroup with the best prognosis featured a strong infiltration by cytotoxic lymphocytes.
  • the worst-prognosis subgroup also displayed a strong immune infiltration, with intermediate expression of lymphocytes' markers and a strong myeloid component, as well as a high signature of endothelial cells and fibroblasts.
  • Further analysis revealed an increased expression of pro-inflammatory and pro-angiogenic molecules in this subgroup, which appear to originate from microenvironment's fibroblasts.
  • the present invention relates to methods for quantifying the population of cells of monocytic origin in a tissue sample.
  • the present invention is defined by the claims.
  • the tumor microenvironment is a complex tissue which contains many distinct cell populations, and whose composition may predict prognosis and response to therapies.
  • the inventors using samples of purified cell populations, the inventors defined specific and robust transcriptomic markers of the immune and stromal cell populations of the tumor microenvironment, and they quantitatively validated them in an in-vitro RNA mixture model.
  • MCP-counter MCP-counter
  • a first object of the present invention relates to a method for quantifying the population of cells of monocytic origin in a tissue sample obtained from a subject comprising determining the expression level of at least one gene selected from the group consisting of CSF1R, ADAP2, RASSF4, FPR3, TFEC, PLA2G7 and KYNU wherein the determined expression level indicates the quantity of the population of cells of monocytic origin in the tissue sample.
  • the term "cells of monocytic origin" has its general meaning in the art.
  • cells of monocytic origin origin include monocytes, macrophages and dendrtic cells.
  • Monocytes are immature myeloid cells which are mostly found in the blood. Upon stimulation by danger signals and/or cytokines, they differentiate into macrophages or myeloid dendritic cells.
  • Macrophages are effector cells arising from monocytes upon entrance in tissues from the peripheral blood. Their major function is phagocytosis, which is the internalization of cells, bacteria or other small bodies, which are then destroyed by acidification, action of proteases and reactive oxygen species. Macrophages are capable of low levels of antigen presentation to CD4+ T lymphocytes.
  • Dendritic cells are specialized antigen-presenting cells (APC).
  • Dendritic cells are capable of phagocytosis, which enable them to present antigens originating from the extracellular milieu to CD4+ T lymphocytes, as well as to CD8+ T cells through a process known as antigen cross-presentation. Apart from phagocytosis, dendritic cells are also capable of macropynocytosis, which is the internalization of small volumes of extracellular fluids, whose antigenic content is subsequently processed and presented.
  • dendritic cells can express co-stimulatory or co-inhibitory ligands, as well as a wide spectrum of cytokines, which depends on their state of maturation and the stimuli they received during maturation. These secondary signals will orientate the functionality of the dendritic cells-stimulated immune cells.
  • a subject denotes a mammal such as a rodent, a feline, a canine and a primate.
  • a subject according to the invention is a human.
  • tissue when used in reference to a part of a body or of an organ, generally refers to an aggregation or collection of morphologically similar cells and associated accessory and support cells and intercellular matter, including extracellular matrix material, vascular supply, and fluids, acting together to perform specific functions in the body.
  • tissue There are generally four basic types of tissue in animals and humans including muscle, nerve, epithelial, and connective tissues.
  • the tissue sample when the subject suffers from a cancer, is a tumor tissue sample.
  • tumor tissue sample means any tissue tumor sample derived from the patient. Said tissue sample is obtained for the purpose of the in vitro evaluation.
  • the tumor sample may result from the tumor resected from the patient.
  • the tumor sample may result from a biopsy performed in the primary tumour of the patient or performed in metastatic sample distant from the primary tumor of the patient.
  • the tumor tissue sample encompasses a global primary tumor (as a whole), a tissue sample from the center of the tumor, a tumor tissue sample collected prior surgery (for follow-up of patients after treatment for example), and a distant metastasis.
  • the tumor tissue sample can, of course, be subjected to a variety of well-known post-collection preparative and storage techniques (e.g., fixation, storage, freezing, etc.).
  • the sample can be fresh, frozen, fixed (e.g., formalin fixed), or embedded (e.g., paraffin embedded.
  • the subject suffers from a solid cancer selected from the group consisting of bile duct cancer (e.g. periphilar cancer, distal bile duct cancer, intrahepatic bile duct cancer), bladder cancer, bone cancer (e.g.
  • osteoblastoma osteochrondroma, hemangioma, chondromyxoid fibroma, osteosarcoma, chondrosarcoma, fibrosarcoma, malignant fibrous histiocytoma, giant cell tumor of the bone, chordoma, lymphoma, multiple myeloma), brain and central nervous system cancer (e.g. meningioma, astocytoma, oligodendrogliomas, ependymoma, gliomas, medulloblastoma, ganglioglioma, Schwannoma, germinoma, craniopharyngioma), breast cancer (e.g.
  • ductal carcinoma in situ infiltrating ductal carcinoma, infiltrating, lobular carcinoma, lobular carcinoma in, situ, gynecomastia
  • Castleman disease e.g. giant lymph node hyperplasia, angiofollicular lymph node hyperplasia
  • cervical cancer colorectal cancer
  • endometrial cancer e.g. endometrial adenocarcinoma, adenocanthoma, papillary serous adnocarcinroma, clear cell
  • esophagus cancer gallbladder cancer (mucinous adenocarcinoma, small cell carcinoma), gastrointestinal carcinoid tumors (e.g.
  • choriocarcinoma chorioadenoma destruens
  • Hodgkin's disease non-Hodgkin's lymphoma, Kaposi's sarcoma
  • kidney cancer e.g. renal cell cancer
  • laryngeal and hypopharyngeal cancer liver cancer (e.g. hemangioma, hepatic adenoma, focal nodular hyperplasia, hepatocellular carcinoma)
  • lung cancer e.g. small cell lung cancer, non-small cell lung cancer
  • mesothelioma plasmacytoma
  • nasal cavity and paranasal sinus cancer e.g.
  • esthesioneuroblastoma midline granuloma
  • nasopharyngeal cancer neuroblastoma
  • oral cavity and oropharyngeal cancer ovarian cancer, pancreatic cancer, penile cancer, pituitary cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma (e.g. embryonal rhabdomyosarcoma, alveolar rhabdomyosarcoma, pleomorphic rhabdomyosarcoma), salivary gland cancer, skin cancer (e.g. melanoma, nonmelanoma skin cancer), stomach cancer, testicular cancer (e.g.
  • thyroid cancer e.g. follicular carcinoma, anaplastic carcinoma, poorly differentiated carcinoma, medullary thyroid carcinoma, thyroid lymphoma
  • vaginal cancer e.g. vulvar cancer
  • uterine cancer e.g. uterine leiomyosarcoma
  • the name of each of the genes of interest refers to the internationally recognised name of the corresponding gene, as found in internationally recognised gene sequences and protein sequences databases, in particular in the database from the HUGO Gene Nomenclature Committee, that is available notably at the following Internet address : http://www.gene.ucl.ac.uk/nomenclature/index.html.
  • the name of each of the various biological markers of interest may also refer to the internationally recognised name of the corresponding gene, as found in the internationally recognised gene sequences and protein sequences databases ENTREZ ID, Genbank, TrEMBL or ENSEMBL.
  • each gene of the present invention is characterized with the probe set name available at the following Internet address http :// genecards .weizmann. ac il/ geneannot/ inde . shtml and their access number available on http://www.ncbi.nlm.nih.gov/gene/ : (see Table A).
  • the expression level of 2, 3, 4, 5, 6 or 7 genes is determined.
  • the combination of genes is selected from the Table 1.
  • the method of the present invention further comprises quantifying at least one further population of cells in the tissue sample.
  • the at least one population of cells is selected from the group consisting of B cells, T cells, NK cells, cytotoxic lymphocytes, neutrophils, myeloid dendritic cells, fibroblasts and endothelial cells (includes lymphatics and blood vessels).
  • the method of the present invention further comprises determining the expression level of at least one gene representative of B cells selected from the group consisting of MS4A1, CD19, CD79A, FCRL2, CR2, PAX5, CD22, BANK1 and IGKC. In some embodiments, the method of the present invention further comprises determining the expression level of at least one gene representative of T cells selected from the group consisting of TRAT1, CD3D, THEMIS, ICOS, SIRPG, CD3G, CTLA4, CD6, CD5 and CD28.
  • the method of the present invention further comprises determining the expression level of at least one gene representative of NK cells selected from the group consisting of KIR2DL1, KIR2DL3, NCR1, KIR3DL1, KIR3DS1, KIR3DL2, SH2D1B, CD160, GENE 2 and KIR2DL4.
  • the method of the present invention further comprises determining the expression level of at least one gene representative of cytotoxic lymphocytes selected from the group consisting of KLRC4-KLRK1 /// KLRK1, CD8A, KLRD1, GNLY, EOMES, KLRC3, KLRC4, FGFBP2 and KLRC1 /// LRC2.
  • the method of the present invention further comprises determining the expression level of at least one gene representative of neutrophils selected from the group consisting of CXCR2, VNN3 CYP4F3, HAL, GENE 1, FCGR3B, KCNJ15, CXCR1, STEAP4 and TNFRSF10C.
  • the method of the present invention further comprises determining the expression level of at least one gene representative of myeloid dendritic cells selected from the group consisting of CD IE, CLECIOA, CLIC2, CD1A, WFDC21P and CD IB.
  • the method of the present invention further comprises determining the expression level of at least one gene representative of fibroblasts selected from the group consisting of DCN, COL6A2, COL6A1, COL3A1, COLlAl, PAMRl, TAGLN and GREM1.
  • the method of the present invention further comprises determining the expression level of at least one gene representative of endothelial cells selected from the group consisting of CDH5, EMCN, MYCT1, ELTD1, ROB04, CLEC14A, VWF, ESAM, MMRN2 and KDR.
  • the expression level of a gene is determined by determining the quantity of mRNA.
  • Methods for determining the quantity of mRNA are well known in the art.
  • the nucleic acid contained in the samples e.g., cell or tissue prepared from the subject
  • the extracted mRNA is then detected by hybridization (e. g., Northern blot analysis, in situ hybridization) and/or amplification (e.g., RT-PCR).
  • Other methods of Amplification include ligase chain reaction (LCR), transcription-mediated amplification (TMA), strand displacement amplification (SDA) and nucleic acid sequence based amplification (NASBA).
  • Nucleic acids having at least 10 nucleotides and exhibiting sequence complementarity or homology to the mRNA of interest herein find utility as hybridization probes or amplification primers. It is understood that such nucleic acids need not be identical, but are typically at least about 80% identical to the homologous region of comparable size, more preferably 85% identical and even more preferably 90-95% identical. In some embodiments, it will be advantageous to use nucleic acids in combination with appropriate means, such as a detectable label, for detecting hybridization.
  • the nucleic acid probes include one or more labels, for example to permit detection of a target nucleic acid molecule using the disclosed probes.
  • a nucleic acid probe includes a label (e.g., a detectable label).
  • a "detectable label” is a molecule or material that can be used to produce a detectable signal that indicates the presence or concentration of the probe (particularly the bound or hybridized probe) in a sample.
  • a labeled nucleic acid molecule provides an indicator of the presence or concentration of a target nucleic acid sequence (e.g., genomic target nucleic acid sequence) (to which the labeled uniquely specific nucleic acid molecule is bound or hybridized) in a sample.
  • a label associated with one or more nucleic acid molecules can be detected either directly or indirectly.
  • a label can be detected by any known or yet to be discovered mechanism including absorption, emission and/ or scattering of a photon (including radio frequency, microwave frequency, infrared frequency, visible frequency and ultra-violet frequency photons).
  • Detectable labels include colored, fluorescent, phosphorescent and luminescent molecules and materials, catalysts (such as enzymes) that convert one substance into another substance to provide a detectable difference (such as by converting a colorless substance into a colored substance or vice versa, or by producing a precipitate or increasing sample turbidity), haptens that can be detected by antibody binding interactions, and paramagnetic and magnetic molecules or materials.
  • detectable labels include fluorescent molecules (or fiuorochromes).
  • fluorescent molecules or fiuorochromes.
  • Numerous fluorochromes are known to those of skill in the art, and can be selected, for example from Life Technologies (formerly Invitrogen), e.g., see, The Handbook— A Guide to Fluorescent Probes and Labeling Technologies).
  • fluorophores that can be attached (for example, chemically conjugated) to a nucleic acid molecule (such as a uniquely specific binding region) are provided in U.S. Pat. No.
  • fluorophores include thiol-reactive europium chelates which emit at approximately 617 mn (Heyduk and Heyduk, Analyt. Biochem. 248:216-27, 1997; J. Biol. Chem. 274:3315-22, 1999), as well as GFP, LissamineTM, diethylaminocoumarin, fluorescein chlorotriazinyl, naphthofluorescein, 4,7-dichlororhodamine and xanthene (as described in U.S. Pat. No. 5,800,996 to Lee et al.) and derivatives thereof.
  • fluorophores known to those skilled in the art can also be used, for example those available from Life Technologies (Invitrogen; Molecular Probes (Eugene, Oreg.)) and including the ALEXA FLUOR® series of dyes (for example, as described in U.S. Pat. Nos. 5,696,157, 6, 130, 101 and 6,716,979), the BODIPY series of dyes (dipyrrometheneboron difiuoride dyes, for example as described in U.S. Pat. Nos.
  • a fluorescent label can be a fluorescent nanoparticle, such as a semiconductor nanocrystal, e.g., a QUANTUM DOTTM (obtained, for example, from Life Technologies (QuantumDot Corp, Invitrogen Nanocrystal Technologies, Eugene, Oreg.); see also, U.S. Pat. Nos.
  • a fluorescent nanoparticle such as a semiconductor nanocrystal, e.g., a QUANTUM DOTTM (obtained, for example, from Life Technologies (QuantumDot Corp, Invitrogen Nanocrystal Technologies, Eugene, Oreg.); see also, U.S. Pat. Nos.
  • Semiconductor nanocrystals are microscopic particles having size-dependent optical and/or electrical properties.
  • a secondary emission of energy occurs of a frequency that corresponds to the handgap of the semiconductor material used in the semiconductor nanocrystal. This emission can he detected as colored light of a specific wavelength or fluorescence.
  • Semiconductor nanocrystals with different spectral characteristics are described in e.g., U.S. Pat. No. 6,602,671.
  • Semiconductor nanocrystals that can he coupled to a variety of biological molecules (including dNTPs and/or nucleic acids) or substrates by techniques described in, for example, Bruchez et al, Science 281 :20132016, 1998; Chan et al., Science 281 :2016-2018, 1998; and U.S. Pat. No. 6,274,323. Formation of semiconductor nanocrystals of various compositions are disclosed in, e.g., U.S. Pat. Nos.
  • semiconductor nanocrystals can he produced that emit light of different colors hased on their composition, size or size and composition.
  • quantum dots that emit light at different wavelengths based on size (565 mn, 655 mn, 705 mn, or 800 mn emission wavelengths), which are suitable as fluorescent labels in the probes disclosed herein are available from Life Technologies (Carlshad, Calif.).
  • Additional labels include, for example, radioisotopes (such as 3 H), metal chelates such as DOTA and DPTA chelates of radioactive or paramagnetic metal ions like Gd3+, and liposomes.
  • Detectable labels that can he used with nucleic acid molecules also include enzymes, for example horseradish peroxidase, alkaline phosphatase, acid phosphatase, glucose oxidase, beta-galactosidase, beta-glucuronidase, or beta-lactamase.
  • enzymes for example horseradish peroxidase, alkaline phosphatase, acid phosphatase, glucose oxidase, beta-galactosidase, beta-glucuronidase, or beta-lactamase.
  • an enzyme can he used in a metallographic detection scheme.
  • SISH silver in situ hybridization
  • Metallographic detection methods include using an enzyme, such as alkaline phosphatase, in combination with a water-soluble metal ion and a redox-inactive substrate of the enzyme. The substrate is converted to a redox-active agent by the enzyme, and the redoxactive agent reduces the metal ion, causing it to form a detectable precipitate.
  • Metallographic detection methods also include using an oxido-reductase enzyme (such as horseradish peroxidase) along with a water soluble metal ion, an oxidizing agent and a reducing agent, again to form a detectable precipitate.
  • an oxido-reductase enzyme such as horseradish peroxidase
  • Probes made using the disclosed methods can be used for nucleic acid detection, such as ISH procedures (for example, fluorescence in situ hybridization (FISH), chromogenic in situ hybridization (CISH) and silver in situ hybridization (SISH)) or comparative genomic hybridization (CGH).
  • ISH procedures for example, fluorescence in situ hybridization (FISH), chromogenic in situ hybridization (CISH) and silver in situ hybridization (SISH)
  • CGH comparative genomic hybridization
  • ISH In situ hybridization
  • a sample containing target nucleic acid sequence e.g., genomic target nucleic acid sequence
  • a metaphase or interphase chromosome preparation such as a cell or tissue sample mounted on a slide
  • a labeled probe specifically hybridizable or specific for the target nucleic acid sequence (e.g., genomic target nucleic acid sequence).
  • the slides are optionally pretreated, e.g., to remove paraffin or other materials that can interfere with uniform hybridization.
  • the sample and the probe are both treated, for example by heating to denature the double stranded nucleic acids.
  • the probe (formulated in a suitable hybridization buffer) and the sample are combined, under conditions and for sufficient time to permit hybridization to occur (typically to reach equilibrium).
  • the chromosome preparation is washed to remove excess probe, and detection of specific labeling of the chromosome target is performed using standard techniques.
  • a biotinylated probe can be detected using fluorescein-labeled avidin or avidin-alkaline phosphatase.
  • fluorochrome detection the fluorochrome can be detected directly, or the samples can be incubated, for example, with fluorescein isothiocyanate (FITC)- conjugated avidin.
  • FITC fluorescein isothiocyanate
  • Amplification of the FITC signal can be effected, if necessary, by incubation with biotin-conjugated goat antiavidin antibodies, washing and a second incubation with FITC- conjugated avidin.
  • samples can be incubated, for example, with streptavidin, washed, incubated with biotin-conjugated alkaline phosphatase, washed again and pre-equilibrated (e.g., in alkaline phosphatase (AP) buffer).
  • AP alkaline phosphatase
  • Numerous reagents and detection schemes can be employed in conjunction with FISH, CISH, and SISH procedures to improve sensitivity, resolution, or other desirable properties.
  • probes labeled with fluorophores including fluorescent dyes and QUANTUM DOTS®
  • fluorophores including fluorescent dyes and QUANTUM DOTS®
  • the probe can be labeled with a nonfluorescent molecule, such as a hapten (such as the following non- limiting examples: biotin, digoxigenin, DNP, and various oxazoles, pyrrazoles, thiazoles, nitroaryls, benzofurazans, triterpenes, ureas, thioureas, rotenones, coumarin, courmarin-based compounds, Podophyllotoxin, Podophyllotoxin-based compounds, and combinations thereof), ligand or other indirectly detectable moiety.
  • a hapten such as the following non- limiting examples: biotin, digoxigenin, DNP, and various oxazoles, pyrrazoles, thiazoles, nitroaryls, benzofurazans, triterpenes, ureas, thioureas, rotenones, coumarin, courmarin-based compounds, Podophyllotoxin,
  • Probes labeled with such non-fluorescent molecules (and the target nucleic acid sequences to which they bind) can then be detected by contacting the sample (e.g., the cell or tissue sample to which the probe is bound) with a labeled detection reagent, such as an antibody (or receptor, or other specific binding partner) specific for the chosen hapten or ligand.
  • a labeled detection reagent such as an antibody (or receptor, or other specific binding partner) specific for the chosen hapten or ligand.
  • the detection reagent can be labeled with a fluorophore (e.g., QUANTUM DOT®) or with another indirectly detectable moiety, or can be contacted with one or more additional specific binding agents (e.g., secondary or specific antibodies), which can be labeled with a fluorophore.
  • the probe, or specific binding agent (such as an antibody, e.g., a primary antibody, receptor or other binding agent) is labeled with an enzyme that is capable of converting a fluorogenic or chromogenic composition into a detectable fluorescent, colored or otherwise detectable signal (e.g., as in deposition of detectable metal particles in SISH).
  • the enzyme can be attached directly or indirectly via a linker to the relevant probe or detection reagent. Examples of suitable reagents (e.g., binding reagents) and chemistries (e.g., linker and attachment chemistries) are described in U.S. Patent Application Publication Nos. 2006/0246524; 2006/0246523, and 2007/ 01 17153.
  • multiplex detection schemes can he produced to facilitate detection of multiple target nucleic acid sequences (e.g., genomic target nucleic acid sequences) in a single assay (e.g., on a single cell or tissue sample or on more than one cell or tissue sample).
  • a first probe that corresponds to a first target sequence can he labelled with a first hapten, such as biotin, while a second probe that corresponds to a second target sequence can be labelled with a second hapten, such as DNP.
  • the bound probes can he detected by contacting the sample with a first specific binding agent (in this case avidin labelled with a first fluorophore, for example, a first spectrally distinct QUANTUM DOT®, e.g., that emits at 585 mn) and a second specific binding agent (in this case an anti-DNP antibody, or antibody fragment, labelled with a second fluorophore (for example, a second spectrally distinct QUANTUM DOT®, e.g., that emits at 705 mn).
  • a first specific binding agent in this case avidin labelled with a first fluorophore, for example, a first spectrally distinct QUANTUM DOT®, e.g., that emits at 585 mn
  • a second specific binding agent in this case an anti-DNP antibody, or antibody fragment, labelled with a second fluorophore (for example, a second spectrally distinct QUANTUM DOT®,
  • Probes typically comprise single-stranded nucleic acids of between 10 to 1000 nucleotides in length, for instance of between 10 and 800, more preferably of between 15 and 700, typically of between 20 and 500.
  • Primers typically are shorter single-stranded nucleic acids, of between 10 to 25 nucleotides in length, designed to perfectly or almost perfectly match a nucleic acid of interest, to be amplified.
  • the probes and primers are "specific" to the nucleic acids they hybridize to, i.e. they preferably hybridize under high stringency hybridization conditions (corresponding to the highest melting temperature Tm, e.g., 50 % formamide, 5x or 6x SCC.
  • SCC is a 0.15 M NaCl, 0.015 M Na-citrate).
  • the nucleic acid primers or probes used in the above amplification and detection method may be assembled as a kit.
  • a kit includes consensus primers and molecular probes.
  • a preferred kit also includes the components necessary to determine if amplification has occurred.
  • the kit may also include, for example, PCR buffers and enzymes; positive control sequences, reaction control primers; and instructions for amplifying and detecting the specific sequences.
  • the methods of the invention comprise the steps of providing total RNAs extracted from cumulus cells and subjecting the RNAs to amplification and hybridization to specific probes, more particularly by means of a quantitative or semiquantitative RT-PCR.
  • the level is determined by DNA chip analysis.
  • DNA chip or nucleic acid microarray consists of different nucleic acid probes that are chemically attached to a substrate, which can be a microchip, a glass slide or a microsphere-sized bead.
  • a microchip may be constituted of polymers, plastics, resins, polysaccharides, silica or silica-based materials, carbon, metals, inorganic glasses, or nitrocellulose.
  • Probes comprise nucleic acids such as cD As or oligonucleotides that may be about 10 to about 60 base pairs.
  • a sample from a test subject optionally first subjected to a reverse transcription, is labelled and contacted with the microarray in hybridization conditions, leading to the formation of complexes between target nucleic acids that are complementary to probe sequences attached to the microarray surface.
  • the labelled hybridized complexes are then detected and can be quantified or semi-quantified. Labelling may be achieved by various methods, e.g. by using radioactive or fluorescent labelling.
  • Many variants of the microarray hybridization technology are available to the man skilled in the art (see e.g. the review by Hoheisel, Nature Reviews, Genetics, 2006, 7:200-210).
  • the nCounter® Analysis system is used to detect intrinsic gene expression.
  • the basis of the nCounter® Analysis system is the unique code assigned to each nucleic acid target to be assayed (International Patent Application Publication No. WO 08/124847, U.S. Patent No. 8,415,102 and Geiss et al. Nature Biotechnology. 2008. 26(3): 317- 325; the contents of which are each incorporated herein by reference in their entireties).
  • the code is composed of an ordered series of colored fluorescent spots which create a unique barcode for each target to be assayed.
  • a pair of probes is designed for each DNA or RNA target, a biotinylated capture probe and a reporter probe carrying the fluorescent barcode.
  • the reporter probe can comprise at a least a first label attachment region to which are attached one or more label monomers that emit light constituting a first signal; at least a second label attachment region, which is non-over-lapping with the first label attachment region, to which are attached one or more label monomers that emit light constituting a second signal; and a first target- specific sequence.
  • each sequence specific reporter probe comprises a target specific sequence capable of hybridizing to no more than one gene and optionally comprises at least three, or at least four label attachment regions, said attachment regions comprising one or more label monomers that emit light, constituting at least a third signal, or at least a fourth signal, respectively.
  • the capture probe can comprise a second target-specific sequence; and a first affinity tag.
  • the capture probe can also comprise one or more label attachment regions.
  • the first target- specific sequence of the reporter probe and the second target- specific sequence of the capture probe hybridize to different regions of the same gene to be detected. Reporter and capture probes are all pooled into a single hybridization mixture, the "probe library".
  • the relative abundance of each target is measured in a single multiplexed hybridization reaction.
  • the method comprises contacting the tumor tissue sample with a probe library, such that the presence of the target in the sample creates a probe pair - target complex.
  • the complex is then purified. More specifically, the sample is combined with the probe library, and hybridization occurs in solution.
  • the tripartite hybridized complexes are purified in a two-step procedure using magnetic beads linked to oligonucleotides complementary to universal sequences present on the capture and reporter probes. This dual purification process allows the hybridization reaction to be driven to completion with a large excess of target-specific probes, as they are ultimately removed, and, thus, do not interfere with binding and imaging of the sample.
  • All post hybridization steps are handled robotically on a custom liquid-handling robot (Prep Station, NanoString Technologies).
  • Purified reactions are typically deposited by the Prep Station into individual flow cells of a sample cartridge, bound to a streptavidin-coated surface via the capture probe,electrophoresed to elongate the reporter probes, and immobilized.
  • the sample cartridge is transferred to a fully automated imaging and data collection device (Digital Analyzer, NanoString Technologies).
  • the level of a target is measured by imaging each sample and counting the number of times the code for that target is detected. For each sample, typically 600 fields-of-view (FOV) are imaged (1376 X 1024 pixels) representing approximately 10 mm2 of the binding surface.
  • FOV fields-of-view
  • Typical imaging density is 100- 1200 counted reporters per field of view depending on the degree of multiplexing, the amount of sample input, and overall target abundance. Data is output in simple spreadsheet format listing the number of counts per target, per sample.
  • This system can be used along with nanoreporters. Additional disclosure regarding nanoreporters can be found in International Publication No. WO 07/076129 and WO07/076132, and US Patent Publication No. 2010/0015607 and 2010/0261026, the contents of which are incorporated herein in their entireties. Further, the term nucleic acid probes and nanoreporters can include the rationally designed (e.g. synthetic sequences) described in International Publication No. WO 2010/019826 and US Patent Publication No.2010/0047924, incorporated herein by reference in its entirety.
  • Expression level of a gene may be expressed as absolute level or normalized level.
  • levels are normalized by correcting the absolute level of a gene by comparing its expression to the expression of a gene that is not a relevant for determining the cancer stage of the subject, e.g., a housekeeping gene that is constitutively expressed.
  • Suitable genes for normalization include housekeeping genes such as the actin gene ACTB, ribosomal 18S gene, GUSB, PG 1 and TFRC. This normalization allows the comparison of the level in one sample, e.g., a subject sample, to another sample, or between samples from different sources.
  • the method of the present invention comprises comparing the determined expression level with a panel of predetermined reference values that correlate with the quantity of the population of cells of monocytic origin determined in a reference tissue sample.
  • the predetermined references values are determined from reference samples wherein the expression level of the gene(s) was (were) determined and adjusted with the exact quantification of the population of cells.
  • a set of reference samples characterized using both gene expression and another measurement technique such as immunohistochemistry, flow cytometry, or RNA can be used for defining the panel of the predetermined reference value. Mixtures of known cellular proportions also can be suitable for determining the predetermined reference values.
  • the method of the present invention is particularly suitable for determining the proportion of the population of cells of monocytic origin in the tissue sample. Typically, when at least one further population of cells is quantified as above described the proportion is determined by any well-known method in the art that typically involves use of algorithm based e.g. on regression models.
  • the method of the present invention is thus suitable for characterizing the immune, endothelial and fibroblastic components of the microenvironment of a tumor to decipher interactions between these cell types that can impact the progression of the tumor and eventually the subject's survival time.
  • the method of the present invention is thus particularly suitable for determining the survival time of a subject suffering from a cancer.
  • OS survival time is generally based on and expressed as the percentage of people who survive a certain type of cancer for a specific amount of time. Cancer statistics often use an overall five-year survival rate. In general, OS rates do not specify whether cancer survivors are still undergoing treatment at five years or if they've become cancer-free (achieved remission). DSF gives more specific information and is the number of people with a particular cancer who achieve remission.
  • progression-free survival (PFS) rates (the number of people who still have cancer, but their disease does not progress) includes people who may have had some success with treatment, but the cancer has not disappeared completely.
  • short survival time indicates that the subject will have a survival time that will be lower than the median (or mean) observed in the general population of subjects suffering from said cancer.
  • long survival time indicates that the subject will have a survival time that will be higher than the median (or mean) observed in the general population of subjects suffering from said cancer.
  • the subject will have a long survival time, it is meant that the subject will have a "good prognosis”.
  • the method of the present invention is also suitable for determining whether a subject suffering from a cancer is eligible or not to anti-cancer treatment.
  • the treatment includes chemotherapy, radiotherapy, and immunotherapy.
  • subject having a short survival time would advantageously receive an anti-cancer treatment.
  • treatment refers to both prophylactic or preventive treatment as well as curative or disease modifying treatment, including treatment of subjects at risk of contracting the disease or suspected to have contracted the disease as well as subjects who are ill or have been diagnosed as suffering from a disease or medical condition, and includes suppression of clinical relapse.
  • the treatment may be administered to a subject having a medical disorder or who ultimately may acquire the disorder, in order to prevent, cure, delay the onset of, reduce the severity of, or ameliorate one or more symptoms of a disorder or recurring disorder, or in order to prolong the survival of a subject beyond that expected in the absence of such treatment.
  • therapeutic regimen is meant the pattern of treatment of an illness, e.g., the pattern of dosing used during therapy.
  • a therapeutic regimen may include an induction regimen and a maintenance regimen.
  • the phrase “induction regimen” or “induction period” refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the initial treatment of a disease.
  • the general goal of an induction regimen is to provide a high level of drug to a subject during the initial period of a treatment regimen.
  • An induction regimen may employ (in part or in whole) a "loading regimen", which may include administering a greater dose of the drug than a physician would employ during a maintenance regimen, administering a drug more frequently than a physician would administer the drug during a maintenance regimen, or both.
  • maintenance regimen refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the maintenance of a subject during treatment of an illness, e.g., to keep the subject in remission for long periods of time (months or years).
  • a maintenance regimen may employ continuous therapy (e.g., administering a drug at a regular intervals, e.g., weekly, monthly, yearly, etc.) or intermittent therapy (e.g., interrupted treatment, intermittent treatment, treatment at relapse, or treatment upon achievement of a particular predetermined criteria [e.g., disease manifestation, etc.]).
  • the treatment consists of administering to the subject a chemotherapeutic agent.
  • chemotherapeutic agent refers to chemical compounds that are effective in inhibiting tumor growth.
  • examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphaorarnide and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone); a carnptothecin (including the synthetic analogue topotecan); bryostatin; callystatin; CC- 1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycin
  • calicheamicin especially calicheamicin (11 and calicheamicin 211, see, e.g., Agnew Chem Intl. Ed. Engl. 33:183-186 (1994); dynemicin, including dynemicin A; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antiobiotic chromomophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, canninomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholino- doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolin
  • paclitaxel (TAXOL®, Bristol-Myers Squibb Oncology, Princeton, N.].) and doxetaxel (TAXOTERE®, Pvhone-Poulenc Rorer, Antony, France); chlorambucil; gemcitabine; 6- thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP- 16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT-1 1 ; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoic acid; capecitabine; and phannaceutically acceptable salts, acids or derivatives of any of the above
  • antihormonal agents that act to regulate or inhibit honnone action on tumors
  • anti-estrogens including for example tamoxifen, raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, LY 117018, onapristone, and toremifene (Fareston); and anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; and phannaceutically acceptable salts, acids or derivatives of any of the above.
  • the treatment consists of administering to the subject a targeted cancer therapy.
  • Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules ("molecular targets") that are involved in the growth, progression, and spread of cancer.
  • Targeted cancer therapies are sometimes called “molecularly targeted drugs,” “molecularly targeted therapies,” “precision medicines,” or similar names.
  • the targeted therapy consists of administering the subject with a tyrosine kinase inhibitor.
  • tyrosine kinase inhibitor refers to any of a variety of therapeutic agents or drugs that act as selective or non-selective inhibitors of receptor and/or non-receptor tyrosine kinases.
  • Tyrosine kinase inhibitors and related compounds are well known in the art and described in U.S Patent Publication 2007/0254295, which is incorporated by reference herein in its entirety. It will be appreciated by one of skill in the art that a compound related to a tyrosine kinase inhibitor will recapitulate the effect of the tyrosine kinase inhibitor, e.g., the related compound will act on a different member of the tyrosine kinase signaling pathway to produce the same effect as would a tyrosine kinase inhibitor of that tyrosine kinase.
  • tyrosine kinase inhibitors and related compounds suitable for use in methods of embodiments of the present invention include, but are not limited to, dasatinib (BMS-354825), PP2, BEZ235, saracatinib, gefitinib (Iressa), sunitinib (Sutent; SU11248), erlotinib (Tarceva; OSI-1774), lapatinib (GW572016; GW2016), canertinib (CI 1033), semaxinib (SU5416), vatalanib (PTK787/ZK222584), sorafenib (BAY 43-9006), imatinib (Gleevec; STI571), lef unomide (SU101), vandetanib (Zactima; ZD6474), MK-2206 (8-[4-aminocyclobutyl)phenyl]-9-phenyl-l,2,4-triazolo[3,
  • the tyrosine kinase inhibitor is a small molecule kinase inhibitor that has been orally administered and that has been the subject of at least one Phase I clinical trial, more preferably at least one Phase II clinical, even more preferably at least one Phase III clinical trial, and most preferably approved by the FDA for at least one hematological or oncological indication.
  • inhibitors include, but are not limited to, Gefitinib, Erlotinib, Lapatinib, Canertinib, BMS- 599626 (AC -480), Neratinib, KRN-633, CEP-11981, Imatinib, Nilotinib, Dasatinib, AZM- 475271, CP-724714, TAK-165, Sunitinib, Vatalanib, CP-547632, Vandetanib, Bosutinib, Lestaurtinib, Tandutinib, Midostaurin, Enzastaurin, AEE-788, Pazopanib, Axitinib, Motasenib, OSI-930, Cediranib, KRN-951, Dovitinib, Seliciclib, SNS-032, PD-0332991, MKC-I (Ro- 317453; R-440), Sorafenib, A
  • the treatment consists of administering to the subject an anti- VEGF agent.
  • an anti-VEGF agent refers to a molecule that inhibits VEGF - mediated angiogenesis, vasculogenesis, or undesirable vascular permeability.
  • an anti-VEGF therapeutic may be an antibody to or other antagonist of VEGF.
  • An "anti-VEGF antibody” is an antibody that binds to VEGF with sufficient affinity and specificity to be useful in a method of the invention.
  • An anti-VEGF antibody will usually not bind to other VEGF homologues such as VEGF- B or VEGF-C, or other growth factors such as P1GF, PDGF or bFGF.
  • a preferred anti- VEGF antibody is a monoclonal antibody that binds to the same epitope as the monoclonal anti-VEGF antibody A4.6.1 produced by hybridoma ATCC® HB 10709 and is a high-affinity anti-VEGF antibody.
  • a "high-affinity anti-VEGF antibody” has at least 10- fold better affinity for VEGF than the monoclonal anti-VEGF antibody A4.6.1.
  • the anti-VEGF antibody is a recombinant humanized anti-VEGF monoclonal antibody fragment generated according to WO 98/45331, including an antibody comprising the CDRs or the variable regions of Y0317. More preferably, anti-VEGF antibody is the antibody fragment known as ranibizumab (LUCENTIS ®).
  • ranibizumab is a humanized, affinity-matured anti-human VEGF Fab fragment.
  • Ranibizumab is produced by standard recombinant technology methods in E. coli expression vector and bacterial fermentation. Ranibizumab is not glycosylated and has a molecular mass of -48,000 daltons. See W098/45331 and U.S. 2003/0190317.
  • Anti-VEGF agents include but are not limited to bevacizumab (rhuMab VEGF, Avastin®, Genentech, South San Francisco Calif), ranibizumab (rhuFAb V2, Lucentis®, Genentech), pegaptanib (Macugen®, Eyetech Pharmaceuticals, New York N.Y.), sunitinib maleate (Sutent®, Pfizer, Groton Conn.)
  • the treatment consists of administering to the subject an immunotherapeutic agent.
  • immunotherapeutic agent refers to a compound, composition or treatment that indirectly or directly enhances, stimulates or increases the body's immune response against cancer cells and/or that decreases the side effects of other anticancer therapies.
  • Immunotherapy is thus a therapy that directly or indirectly stimulates or enhances the immune system's responses to cancer cells and/or lessens the side effects that may have been caused by other anti-cancer agents.
  • Immunotherapy is also referred to in the art as immunologic therapy, biological therapy biological response modifier therapy and biotherapy.
  • immunotherapeutic agents examples include, but are not limited to, cytokines, cancer vaccines, monoclonal antibodies and non-cytokine adjuvants.
  • the immunotherapeutic treatment may consist of administering the subject with an amount of immune cells (T cells, NK, cells, dendritic cells, B cells).
  • Immunotherapeutic agents can be non-specific, i.e. boost the immune system generally so that the human body becomes more effective in fighting the growth and/or spread of cancer cells, or they can be specific, i.e. targeted to the cancer cells themselves immunotherapy regimens may combine the use of non-specific and specific immunotherapeutic agents.
  • Non-specific immunotherapeutic agents are substances that stimulate or indirectly improve the immune system.
  • Non-specific immunotherapeutic agents have been used alone as a main therapy for the treatment of cancer, as well as in addition to a main therapy, in which case the non-specific immunotherapeutic agent functions as an adjuvant to enhance the effectiveness of other therapies (e.g. cancer vaccines).
  • Non-specific immunotherapeutic agents can also function in this latter context to reduce the side effects of other therapies, for example, bone marrow suppression induced by certain chemotherapeutic agents.
  • Non-specific immunotherapeutic agents can act on key immune system cells and cause secondary responses, such as increased production of cytokines and immunoglobulins. Alternatively, the agents can themselves comprise cytokines.
  • Non-specific immunotherapeutic agents are generally classified as cytokines or non-cytokine adjuvants.
  • cytokines have found application in the treatment of cancer either as general non-specific immunotherapies designed to boost the immune system, or as adjuvants provided with other therapies.
  • Suitable cytokines include, but are not limited to, interferons, interleukins and colony-stimulating factors.
  • Interferons contemplated by the present invention include the common types of IFNs, IFN-alpha (IFN-a), IFN-beta (IFN- ⁇ ) and IFN-gamma (IFN- ⁇ ).
  • IFNs can act directly on cancer cells, for example, by slowing their growth, promoting their development into cells with more normal behaviour and/or increasing their production of antigens thus making the cancer cells easier for the immune system to recognise and destroy.
  • IFNs can also act indirectly on cancer cells, for example, by slowing down angiogenesis, boosting the immune system and/or stimulating natural killer (NK) cells, T cells and macrophages.
  • Recombinant IFN-alpha is available commercially as Roferon (Roche Pharmaceuticals) and Intron A (Schering Corporation).
  • Interleukins contemplated by the present invention include IL-2, IL-4, IL-11 and IL-12.
  • Examples of commercially available recombinant interleukins include Proleukin® (IL-2; Chiron Corporation) and Neumega® (IL-12; Wyeth Pharmaceuticals).
  • Zymogenetics, Inc. (Seattle, Wash.) is currently testing a recombinant form of IL-21, which is also contemplated for use in the combinations of the present invention.
  • Colony- stimulating factors contemplated by the present invention include granulocyte colony stimulating factor (G-CSF or filgrastim), granulocyte-macrophage colony stimulating factor (GM-CSF or sargramostim) and erythropoietin (epoetin alfa, darbepoietin).
  • G-CSF granulocyte colony stimulating factor
  • GM-CSF granulocyte-macrophage colony stimulating factor
  • erythropoietin epoetin alfa, darbepoietin.
  • G-CSF Neupogen®
  • Amgen Neulasta
  • GM-CSF Leukine
  • Berlex Procrit
  • Epogen erythropoietin
  • Arnesp erytropoietin
  • immunotherapeutic agents can be active, i.e. stimulate the body's own immune response, or they can be passive, i.e. comprise immune system components that were generated external to the body.
  • Passive specific immunotherapy typically involves the use of one or more monoclonal antibodies that are specific for a particular antigen found on the surface of a cancer cell or that are specific for a particular cell growth factor.
  • Monoclonal antibodies may be used in the treatment of cancer in a number of ways, for example, to enhance a subject's immune response to a specific type of cancer, to interfere with the growth of cancer cells by targeting specific cell growth factors, such as those involved in angiogenesis, or by enhancing the delivery of other anticancer agents to cancer cells when linked or conjugated to agents such as chemotherapeutic agents, radioactive particles or toxins.
  • the immunotherapeutic agent is an immune checkpoint inhibitor.
  • immune checkpoint inhibitor refers to molecules that totally or partially reduce, inhibit, interfere with or modulate one or more checkpoint proteins.
  • Checkpoint proteins regulate T-cell activation or function. Numerous checkpoint proteins are known, such as CTLA-4 and its ligands CD 80 and CD86; and PDl with its ligands PDLl and PDL2 (Pardoll, Nature Reviews Cancer 12: 252-264, 2012). These proteins are responsible for co-stimulatory or inhibitory interactions of T-cell responses.
  • Immune checkpoint proteins regulate and maintain self-tolerance and the duration and amplitude of physiological immune responses. Immune checkpoint inhibitors include antibodies or are derived from antibodies.
  • the immune checkpoint inhibitor is an antibody selected from the group consisting of anti-CTLA4 antibodies (e.g. Ipilimumab), anti-PDl antibodies, anti-PDLl antibodies, anti-TIMP3 antibodies, anti-LAG3 antibodies, anti-B7H3 antibodies, anti-B7H4 antibodies, anti-BTLA antibodies, and anti-B7H6 antibodies.
  • anti-CTLA4 antibodies e.g. Ipilimumab
  • anti-PDl antibodies e.g. Ipilimumab
  • anti-PDLl antibodies anti-TIMP3 antibodies
  • anti-LAG3 antibodies anti-B7H3 antibodies
  • anti-B7H4 antibodies anti-BTLA antibodies
  • anti-B7H6 antibodies anti-B7H6 antibodies.
  • anti-CTLA-4 antibodies are described in US Patent Nos: 5,811,097; 5,811,097; 5,855,887; 6,051,227; 6,207,157; 6,682,736; 6,984,720; and 7,605,238.
  • the anti-CTLA-4 antibody is ipilimumab (also known as 10D1, MDX-D010) a fully human monoclonal IgG antibody that binds to CTLA-4.
  • Another immune checkpoint protein is programmed cell death 1 (PD-1). Examples of PD-1 and PD-11 blockers are described in US Patent Nos. 7,488,802; 7,943,743; 8,008,449; 8,168,757; 8,217,149, and PCT Published Patent Application Nos: WO03042402, WO2008156712, WO2010089411, WO2010036959, WO2011066342, WO2011159877, WO2011082400, and WO2011161699.
  • the PD-1 blockers include anti- PD-L1 antibodies.
  • the PD-1 blockers include anti-PD-1 antibodies and similar binding proteins such as nivolumab (MDX 1106, BMS 936558, ONO 4538), a fully human IgG4 antibody that binds to and blocks the activation of PD-1 by its ligands PD-Ll and PD-L2; lambrolizumab (MK-3475 or SCH 900475), a humanized monoclonal IgG4 antibody against PD-1 ; CT-011 a humanized antibody that binds PD-1 ; AMP-224 is a fusion protein of B7-DC; an antibody Fc portion; BMS-936559 (MDX- 1105-01) for PD-Ll (B7-H1) blockade.
  • nivolumab MDX 1106, BMS 936558, ONO 4538
  • MK-3475 or SCH 900475 lambrolizumab
  • CT-011
  • immune-checkpoint inhibitors include lymphocyte activation gene-3 (LAG-3) inhibitors, such as IMP321, a soluble Ig fusion protein (Brignone et al, 2007, J. Immunol. 179:4202- 4211).
  • Other immune-checkpoint inhibitors include B7 inhibitors, such as B7-H3 and B7-H4 inhibitors.
  • the anti-B7-H3 antibody MGA271 (Loo et al., 2012, Clin. Cancer Res. July 15 (18) 3834).
  • TIM3 T-cell immunoglobulin domain and mucin domain 3) inhibitors (Fourcade et al., 2010, J. Exp. Med. 207:2175-86 and Sakuishi et al., 2010, J. Exp. Med. 207:2187-94).
  • the immunotherapeutic treatment consists of an adoptive immunotherapy as described by Nicholas P. Restifo, Mark E. Dudley and Steven A. Rosenberg "Adoptive immunotherapy for cancer: harnessing the T cell response, Nature Reviews Immunology, Volume 12, April 2012).
  • adoptive immunotherapy the patient's circulating lymphocytes, or tumor infiltrated lymphocytes, are isolated in vitro, activated by lymphokines such as IL-2 and readministered (Rosenberg et al., 1988; 1989).
  • the activated lymphocytes are most preferably be the patient's own cells that were earlier isolated from a blood sampke and activated (or "expanded") in vitro.
  • the subject is administered with host cells that express a chimeric antigen receptor.
  • chimeric antigen receptor or “CAR” has its general meaning in the art and refers to an artificially constructed hybrid protein or polypeptide containing the antigen binding domains of an antibody (e.g., scFv) linked to T- cell signaling domains. Characteristics of CARs include their ability to redirect T- cell specificity and reactivity toward a selected target in a non-MHC -restricted manner, exploiting the antigen-binding properties of monoclonal antibodies.
  • T cells expressing CARs the ability to recognize antigen independent of antigen processing, thus bypassing a major mechanism of tumor escape.
  • CARs advantageously do not dimerize with endogenous T cell receptor (TCR) alpha and beta chains.
  • TCR T cell receptor
  • the host cell can be of any cell type, can originate from any type of tissue, and can be of any developmental stage, the host cell is a T cell, e.g. isolated from peripheral blood lymphocytes (PBL) or peripheral blood mononuclear cells (PBMC).
  • PBL peripheral blood lymphocytes
  • PBMC peripheral blood mononuclear cells
  • the T cell can be any T cell, such as a cultured T cell, e.g., a primary T cell, or a T cell from a cultured T cell line, e.g., Jurkat, SupTl, etc., or a T cell obtained from a mammal. If obtained from a mammal, the T cell can be obtained from numerous sources, including but not limited to blood, bone marrow, lymph node, the thymus, or other tissues or fluids. T cells can also be enriched for or purified.
  • a cultured T cell e.g., a primary T cell
  • a T cell from a cultured T cell line e.g., Jurkat, SupTl, etc.
  • T cell obtained from a mammal e.g., the T cell can be obtained from numerous sources, including but not limited to blood, bone marrow, lymph node, the thymus, or other tissues or fluids. T cells can also be enriched for or purified.
  • the T cell can be any type of T cell and can be of any developmental stage, including but not limited to, CD4+/CD8+ double positive T cells, CD4+ helper T cells, e.g., Th2 cells, CD8+ T cells (e.g., cytotoxic T cells), tumor infiltrating cells, memory T cells, naive T cells, and the like.
  • the T cell may be a CD8+ T cell or a CD4+ T cell.
  • the population of those T cells prepared as described above can be utilized in methods and compositions for adoptive immunotherapy in accordance with known techniques, or variations thereof that will be apparent to those skilled in the art based on the instant disclosure. See, e.g., US Patent Application Publication No.
  • Adoptive immunotherapy of cancer refers to a therapeutic approach in which immune cells with an antitumor reactivity are administered to a tumor- bearing host, with the aim that the cells mediate either directly or indirectly, the regression of an established tumor. Transfusion of lymphocytes, particularly T lymphocytes, falls into this category.
  • autolymphocyte therapies ALT
  • these therapies involve processing the patient's own lymphocytes to either enhance the immune cell mediated response or to recognize specific antigens or foreign substances in the body, including the cancer cells.
  • the treatments are accomplished by removing the patient's lymphocytes and exposing these cells in vitro to biologies and drugs to activate the immune function of the cells. Once the autologous cells are activated, these ex vivo activated cells are reinfused into the patient to enhance the immune system to treat cancer.
  • the cells are formulated by first harvesting them from their culture medium, and then washing and concentrating the cells in a medium and container system suitable for administration (a "pharmaceutically acceptable" carrier) in a treatment-effective amount.
  • Suitable infusion medium can be any isotonic medium formulation, typically normal saline, Normosol R (Abbott) or Plasma-Lyte A (Baxter), but also 5% dextrose in water or Ringer's lactate can be utilized.
  • the infusion medium can be supplemented with human serum albumin.
  • a treatment-effective amount of cells in the composition is dependent on the relative representation of the T cells with the desired specificity, on the age and weight of the recipient, on the severity of the targeted condition and on the immunogenicity of the targeted Ags. These amount of cells can be as low as approximately 10 /kg, preferably 5xl0 3 /kg; and as high as 10 7 /kg, preferably 10 8 /kg.
  • the number of cells will depend upon the ultimate use for which the composition is intended, as will the type of cells included therein. For example, if cells that are specific for a particular Ag are desired, then the population will contain greater than 70%, generally greater than 80%, 85% and 90-95% of such cells. For uses provided herein, the cells are generally in a volume of a liter or less, can be 500 ml or less, even 250 ml or 100 ml or less. The clinically relevant number of immune cells can be apportioned into multiple infusions that cumulatively equal or exceed the desired total amount of cells.
  • the immunotherapeutic treatment may consist of allografting, in particular, allograft with hematopoietic stem cell HSC.
  • the immunotherapeutic treatment may also consist in an adoptive immunotherapy as described by Nicholas P. Restifo, Mark E. Dudley and Steven A. Rosenberg "Adoptive immunotherapy for cancer: harnessing the T cell response, Nature Reviews Immunology, Volume 12, April 2012).
  • adoptive immunotherapy the subject's circulating lymphocytes, NK cells, are isolated amplified in vitro and readministered to the subject.
  • the activated lymphocytes or NK cells are most preferably be the subject's own cells that were earlier isolated from a blood or tumor sample and activated (or "expanded") in vitro.
  • the treatment consists of administering to the subject a radiotherapeutic agent.
  • radiotherapeutic agent as used herein, is intended to refer to any radiotherapeutic agent known to one of skill in the art to be effective to treat or ameliorate cancer, without limitation.
  • the radiotherapeutic agent can be an agent such as those administered in brachytherapy or radionuclide therapy.
  • Such methods can optionally further comprise the administration of one or more additional cancer therapies, such as, but not limited to, chemotherapies, and/or another radiotherapy.
  • transcriptomic profiles from several types of samples (Microenvironment Cell Populations (MCP), non-hematopoietic human tumors, non- diseased human tissues, in-vitro RNA mixtures) obtained from different gene expression platforms (mainly Affymetrix HGU 133 Plus 2.0, HGU 133A, HuGene 1.0 ST and Illumina HiSeq 2000) .
  • MCP Microenvironment Cell Populations
  • HGU 133 Plus 2.0, HGU 133A, HuGene 1.0 ST and Illumina HiSeq 2000 For survival analysis, transcriptomic profiles of non-hematopoietic human tumors with Overall Survival annotations were also included.
  • the table below lists the types of samples curated, stratified by gene expression platforms, and points to the identifiers of the included samples. 2.
  • Affymetrix Human Genome 133 Plus 2.0, Human Genome 133A, HuGene 1.0 ST arrays MCP datasets and tumor datasets from Affymetrix Human Genome 133 Plus 2.0, Human Genome 133A, HuGene 1.0 ST arrays were normalized using the frozen robust multiarray average (fRMA) method, implemented in the 'fRMA' R package (version 1.18.0). Unlike RMA, fRMA uses fixed estimates of probe-specific effects and variances, allowing a consistent normalization of GEP from different series, provided that they were obtained on the same gene expression platform.
  • fRMA frozen robust multiarray average
  • Samples' annotations were retrieved from GEO:GSE7307. Samples corresponding to diseased tissues, cell lines or sorted immune cells were discarded, retaining only the non- diseased cellularly-heterogeneous samples. For clarity, some tissues were regrouped in broader anatomical locations (data not shown). Anatomical systems were manually added.
  • Annotations for samples retrieved from GEO were retrieved from the 'Series matrix' files (respectively from 'sdrf files).
  • Annotations for TCGA samples were retrieved from the TCGA data portal (https://tcga- data.nci.nih.gov/tcga/dataAccessMatrix.htm).
  • Non-hematopoietic tumor samples series (Other platforms)
  • Some tumor GEP are present in multiple public datasets and correctly labeled as 'Reanalyzed'. In this case, only the original sample was considered for analysis.
  • pyramid a directed acyclic graph with a root node.
  • Samples of microenvironment purified cells were labeled according to their reported immune or stromal populations, resulting in 63 distinct labels in the MCP discovery series, with an addition of 15 labels for the MCP validation series, resulting in a total of 78 labels.
  • the labels "CD8+ T cells”, “CD4+ T cells”, “ ⁇ cells”, “Memory T cells”, “Activated T cells” and “Naive T cells”, and all labels included in them form the "T cells” category, which itself is included in the "T/NK lineage” category.
  • T cells category
  • PBMC Peripheral-Blood Mononuclear Cells
  • 'mixed samples' are those whose label is partly overlapping with the category (some cells of the sample are in C and some are in C ).
  • C is the set of samples whose label is "CD8 T cells” or "Effector memory CD8 T cells” (Supplementary Figure SI, Supplementary Table SI 2), mixed samples are for instance CD3+ T cells as they mix CD4+ and CD8+ T cells, or PBMC as they mix CD8+ T cells with e.g. monocytes. C is defined as all non-positive non-mixed samples.
  • probeset-level statistics was computed per probeset: the positive Area Under the ROC Curve (AUC), the fold-change (FC) and a specific fold-change (sFC), with the latter-two with the following definitions:
  • a MCP-counter score Given a set of transcriptomic markers of a given category, we computed a corresponding per-sample score, called hereafter a MCP-counter score, using the log2 geometric mean of this set of markers.
  • TMs For a given set of TMs, corresponding features were subsetted from the expression matrices of the three MCP series and three primary tumor series (Affymetrix 133 Plus 2.0, 133A, and TCGA). On these six matrices, Pearson correlation coefficients were computed for each pair of features.
  • Peripheral venous blood was extracted for 3 healthy donor using heparin vacuntainer tubes (BD Bioscience).
  • Peripheral blood mononuclear (PBMC) or polymorphonuclear cells (PMN) were isolated using Ficoll-Paque PLUS (GE Healthcare Life Sience) or Polymorph Prep (Axis-Shield) density gradient, respectively.
  • PBMCs were stained with anti-CD3 FITC (Clone UCHTl), anti-CD14 APC ( ⁇ 9), anti-CD19 ECD (J3-119) and anti-CD56 PE (B159); and PMNs with anti-CD66b FITC (G10F5), anti-CD 19 ECD (J3-119), anti-CD3 PE (UCHTl), anti- CD56 PE (B159) and anti-CD14 APC ( ⁇ 9).
  • Cell sorting was done in a FACS Aria cytometer (BD Bioscience), and cell purity higher than 97% was always achieved.
  • T cells DAPI-/CD3+/CD14-/CD19-/CD56-
  • monocytes DAPI- /CD3-/CD14+/CD19-/CD56-
  • B cells DAPI-/CD3-/CD14-/CD19+/CD56-
  • NK cells DAPI-/CD3-/CD14-/CD19-/CD56+
  • neutrophils DAPI-/CD66b+/CD19- /CD3-/CD56-/CD14-
  • HCT116 were purchased from ATCC and cultured according to vendor's instructions. RNA extraction
  • Biotinylated double strand cDNA targets were prepared from 10 ng of total RNA using the NuGEN Ovation Pico WTA System V2 Kit (Cat # 3302) followed by the NuGEN Encore Biotin Module Kit (Cat # 4200) according to manufacturer recommendations. Following fragmentation and labeling, 4.55 ⁇ g of cDNAs were hybridized for 16 hours at 45°C, 60 rpm on Human GeneChip HG-U133 plus 2.0 arrays (Affymetrix). The chips were washed and stained in the GeneChip Fluidics Station 450 (Affymetrix) using the FS450_0004 script and scanned with the GeneChip Scanner 3000 7G (Affymetrix) at a resolution of 1.56 ⁇ . Raw data (.CEL Intensity files) were extracted from the scanned images using the Affymetrix GeneChip Command Console (AGCC) version 4.0.
  • Affymetrix GeneChip Command Console
  • MCP-counter scores were computed from the fRMA-normalized RNA-mixture microarray dataset and plotted against the known mRNA log-proportions. Pearson correlation coefficients and the corresponding tests against the t distribution were performed.
  • the MCP-counter scores for non-hematopoietic samples from the 'MCP Discovery series' were computed.
  • the above-described linear fits were used to predict the mRNA fraction of the five sorted cell populations from the corresponding MCP-counter scores.
  • the exponential of the mean of the estimated log-proportions across non-hematopoietic samples is reported as the estimate of the limit of detection for each immune cell population assayed.
  • transcriptome data of the 12 mixture samples has been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE64385.
  • probesets were mapped to genes identifiers using annotations provided by Affymetrix version 35.
  • TCGA GEP are annotated with ENTREZ identifiers which were converted to HUGO symbols using ftp ://ftp .ncbi .nih. gov/ gene/DAT A GENE_INFO/Mammalia/Homo_sapiens . gene_info . gz (retrieved on 201 _05_20).
  • MCP-counter we implemented MCP-counter as an R package called 'MCPcounter'. Users should call the 'MCPcounter. estimate' function, which takes a normalized gene expression matrix as its first argument, and the type of features that should be mapped to selected transcriptomic markers (probesets, HUGO symbols, ENTREZ ID) as its second argument.
  • Figure 4a represents, for each cell population, the mean MCP-counter scores or CIBERSORT estimates for a given value of w across the 50 simulations.
  • CIBERSORT non-zero estimates of non-introduced cell populations (for instance Mast cells) were discarded, and the remaining estimates were re-normalized to sum to 1.
  • estimates for sub- populations were summed (for instance, the 'B cells' CIBERSORT estimate sums the estimates corresponding to 'B cells naive', 'B cells memory' and 'Plasma cells' subpopulations).
  • TM sets proposed by Bindea et al. (the "Immunome” TM set) and Yoshihara et al. (“ESTIMATE” TM set) were retrieved from the corresponding publication and the ESTIMATE R package, respectively.
  • probesets were used as TM for the Affymetrix 133 Plus 2.0 and 133A MCP series, and gene symbols for the HuGene 1.0 ST MCP series.
  • ESTIMATE gene symbols were used for all three series.
  • MCP-counter estimates were first computed for each dataset individually. The resulting scores were then Z-transformed for each dataset individually, leading to similar distributions of the scores across datasets. Datasets from the same cancer were then merged, and all MCP- counter variables were binarized using a median cut (leading to "High” and “Low” samples for each variable and for each cancer according to their relative position from the cancer's median value).
  • We selected three tumor classifications from the literature using B and T cells in lung adenocarcinoma, fibroblasts and cytotoxic lymphocytes in colorectal cancer, and macrophages and cytotoxic lymphocytes in breast cancer).
  • MCP-counter a method that objective is to measure an inter- samples relative abundance of different microenvironment cell populations.
  • MCP-counter is based on the methodological framework of transcriptomic markers (TM), defined as gene-expression features expressed in one and only one cell population, and whose expression shows little variation within the population of interest (step 1). It directly follows that within a sample composed of many different cell populations, the abundance of the population of interest is proportional to the sample's expression of its related TM. Given their restrictive definition, TM are not guaranteed to exist for all populations.
  • TM transcriptomic markers
  • MCP Microenvironment Cell Populations
  • TM of a given cell population (a node in our cell populations pyramid) (step 5), we defined as 'positive' the samples included in this population, and we defined as 'negative' the samples that do not contain this population. Samples containing both 'positive' and 'negative' cells are omitted from the analysis for this node.
  • TMs specific for 10 distinct populations 8 immune cell populations (T cells, CD8+ T cells, NK cells, cytotoxic lymphocytes, cells of the B lineage, of the monocytic lineage, myeloid dendritic cells, and neutrophils), and 2 non- immune stromal populations (endothelial cells and fibroblasts).
  • the 81 datasets from the Discovery set spanned 344 different culture conditions, purifications methods and cell treatments, which ensures that the selection of TM was not sensitive to experimental conditions.
  • MCP-counter scores were defined as the log2 average expression of the TM for each population (step 6). We then validated MCP-counter (step 7).
  • the reproducibility of the identified TM was assessed on two validation series of 1596 samples hybridized on 'Affymetrix_U133A' arrays and 3208 samples hybridized on 'Affymetrix HuGene l.OST' arrays (data not shown).
  • the specific expression patterns obtained on the discovery series were consistently reproduced (data not shown), and the same selection criteria applied to MCP validation series identified significantly overlapping TM sets (data not shown).
  • MCP-counter scores exhibit a clear separation of the cell types on the discovery and two validation series (data not shown), with an AUC above 0.994 for each signature on the 4804 validation samples (data not shown).
  • TM largely overlap with known markers of the corresponding cell populations. They include for instance probesets mapping to CD3D and CD5 for T cells, CD8B for CD8+ T cells, EOMES and GNLY for cytotoxic lymphocytes, NCR1 (NKp46) and KIR genes for NK cells, CD 19, CD79A and CD79B for B cells, CSF1R for monocytic cells, CD1 molecules for myeloid dendritic cells, FCGR3B and CEACAM3 (CD66b) for neutrophils, VWF (von Willebrand Factor) and CDH5 (VE-cadherin) for endothelial cells, and DCN and TAGLN for fibroblasts (data not shown).
  • TM some genes usually considered as specific for a given cell population, such as BLK that we found overexpressed not only in B cells but also at a lower level in plasmacytoid dendritic cells, a result which supports the relevance of a data-driven approach (data not shown).
  • Transcriptome analyses revealed that MCP-counter scores were highly correlated with the cells' proportions in the mixtures (data not shown), with Pearson's correlation coefficients ranging from 0.94 to 0.99.
  • immunohistochemical (IHC) digital quantifications of CD3+, CD8a+ and CD68+ cell densities were performed on tissue sections from 38 colorectal-cancer tumors. The IHC-measured densities of each cell population was found to correlate with the corresponding MCP-counter score (data not shown).
  • MCP-counter differs from methods such as CIBERSORT, which aims to measure intra- sample, within leukocytes, proportions of immune cell populations, while MCP-counter outputs an abundance estimate per cell population that enables an inter-sample comparison, at the cost of being expressed in arbitrary units.
  • CIBERSORT aims to measure intra- sample, within leukocytes, proportions of immune cell populations
  • MCP-counter outputs an abundance estimate per cell population that enables an inter-sample comparison, at the cost of being expressed in arbitrary units.
  • Lymphoid organs (Spleen, lymph nodes, tonsils, bone marrow) were, as expected, found to harbor a high number of immune cells, while the thymus featured the highest MCP-counter score for CD3+ T cells (data not shown).
  • known "immune sanctuaries" such as testes were correctly found to feature little abundance of immune cells.
  • Tumor immunology is one of the natural applications of MCP-counter.
  • the MCP-scores obtained from the three underlying transcriptome platforms ('Affymetrix_HGU_133_Plus_2.0', 'Affymetrix_133A' and Illumina HiSeq) yielded reproducible patterns across cancer types (data not shown) and were thus averaged to produce a synthetic view (data not shown).
  • kidney clear-cell carcinoma had the highest abundance of endothelial cells of all cancers, while uveal melanomas, which occur in the eye, an immune sanctuary, are poorly infiltrated by immune cells. Colorectal cancer samples were average in terms of immune cells abundance. Gliomas and glioblastomas appeared poorly-infiltrated by T cells. The often viral- induced cervical squamous carcinoma is highly infiltrated by cytotoxic T and NK cells, but poorly by cells of monocytic origin.
  • the three tumor series included respectively 2631, 1615 and 6047 Overall- Survival
  • MCP-counter was relevant to identify tumor subgroups based on their relative infiltration by multiple cell populations.
  • lung non-small cell adenocarcinoma it was recently reported that infiltration by B or T cells independently predict favorable prognosis.
  • colorectal cancer extensive literature exists about the protective role of a high infiltration by T cells, while fibroblasts were reported to be associated with poor outcome.
  • breast cancer a stratification relying on cytotoxic T cells (associated with favorable outcome) and macrophages (poor outcome) was proposed. Using MCP-counter, we were able to reproduce these clinically- relevant patterns (data not shown).
  • Tissue-infiltrating immune and non-immune stromal cells contribute to the measured signal in gene expression experiments. Retrieving this information can yield estimates of the abundance of tissue -infiltrating cells, illustrated herein in cancer samples.
  • MCP Microenvironment Cell Population
  • MCP-counter' s lower limit of detection for a population was below 2% of the sample's total RNA proportion when using 'Affymetrix_HGU_133_Plus_2.0' microarrays. This limit of detection might be lowered by using more sensitive gene expression techniques, such as rt-qPCR, Nanostring, or RNA-sequencing assays.
  • MCP-counter estimates are conceptually close to IHC-estimated cell densities (number of cells per surface unit on a tissue section), as the produced estimates can be used to compare the abundance of the corresponding cell populations across samples.
  • MCP-counter enables the simultaneous quantification of 10 cell populations with a single gene-expression experiment, while IHC quantifications are usually limited to a couple of markers. The information of the cells' spatial localization, which is available in IHC experiments, is however lost when using transcriptomic technologies.
  • MCP-counter is more sensitive and specific in the interpretation of its scores than other previously-published TM-based methods, through a rigorous, unbiased and conservative approach to define the TM sets on which it is based (data not shown). These methods were also limited to only two populations, or were not quantitatively validated. It conceptually differs from flow cytometry (FC) experiments or FC-inspired computational methods such as CIBERSORT, which aim at describing the relative proportions of various cell populations within a single sample (data not shown). In contrast, MCP-counter is specifically designed to compare the absolute abundance of a given cell population across multiple samples.
  • MCP-counter scores linearly correlate with the corresponding cell population's abundances across samples, but are expressed in arbitrary units. These arbitrary units are dependent on the gene expression platform used to produce the data and one can only compare samples produced with the same gene expression platforms. Nonetheless, we showed that the relative cellular abundance across three large tumor datasets, totaling more than 19,000 tumors, and obtained with three different gene expression platform, are largely consistent (data not shown), legitimating the use of MCP-counter to assess which samples are most or least infiltrated by each characterized cell population.
  • MCP-counter On non-diseased human tissues where we observed abundance estimates consistent with known immunological status of the samples.
  • MCP-counter to describe the average MCP cellular abundances in 32 non- hematopoietic human malignancies. This analysis confirmed the very high vascularization of clear-cell renal-cell carcinoma, and showed that cervical squamous cell carcinoma tumors, which are often virally-induced, are highly infiltrated by T lymphocytes, and notably cytotoxic T cells, but only moderately by other immune subsets.
  • MCP-counter is most relevant to stratify a cohort of similar samples based on the composition of their immune and stromal microenvironments, or to follow the composition of the microenvironment over time.
  • the use of MCP-counter confirmed that significant univariate association between OS and tumor infiltration by cytotoxic lymphocytes were mostly positive.
  • significant associations between prognosis and extensive abundance of non- immune stromal cell populations, and notably fibroblasts, are shown mostly negative using MCP-counter.
  • MCP-counter complements IHC approaches in that it enables the analysis of 10 cell populations using a single gene expression experiment.
  • MCP-counter relies on TM which have been identified in a dataset containing GEP of cancer cell lines from 21 different anatomic locations among its negative controls, ensuring applicability in a wide range of samples.
  • This large diversity of control samples may however discard TM which would be relevant in a specific setting: for instance, the screening procedure discarded NCAM 1 (CD56), a widely-used marker of NK cells, as it is also expressed by nervous malignant cells, and is thus unsuitable to quantify NK cells in brain samples.
  • NCAM 1 CD56
  • the general framework that we developed herein could thus be tailored to identify additional TM for investigation in a more restricted set of organs.
  • MCP-counter can be incorporated in clinical routine to characterize immune infiltration in samples where IHC-based quantifications are impossible, such as for fine-needle aspiration biopsies. In this setting, samples are typically collected one at a time. To complement the current multi-sample use of MCP-counter, designed for exploratory analyses, one could notably settle on a desired gene expression platform and use a set of calibrating samples. For instance, in- vitro RNA mixtures described herein could help mapping MCP-counter abundance scores to non-arbitrary units, such as the percentage of the corresponding cells within a sample.
  • MCP-counter is the first validated computational method that enables a robust quantification of the abundance of multiple immune and non-immune stromal populations in the transcriptome of cellularly-heterogeneous tissues such as normal or malignant tissues. It might be relevant in a clinical setting, as immune biomarkers can help predict patient's prognosis or response to therapies, most notably to immunotherapies. Its retrospective and prospective application to study inflammatory profiles through transcriptomics should help unraveling the role of immune and stromal populations in cancers and other diseases, and help decipher the interplay between these populations.
  • Table 1 Gene signatures for quantifying the population of cells of monocytic origin and others cells in a tissue sample.
  • Complete gene signatures were obtained based on the methodology described in EXAMPLE. In this example, it is shown that the complete signatures are able to predict corresponding cell types' proportions in a heterogeneous tissue.
  • S be a signature, composed of n probesets fi ⁇ i ⁇ n.
  • 9697 tumor transcriptomes from multiple cancer types were obtained from public repositories. Expression values for each probesets were mean-centered across samples (row centering). The expression values from probesets within S were then averaged to obtain a single representative value for each sample : meani ⁇ i ⁇ n(f).
  • Combinations were ranked according to their ability to correlate with in-vitro RNA proportions, if available or with their ability to correlate to the summarized expression of the complete set of marker.

Abstract

La présente invention concerne des procédés de quantification de la population de cellules d'origine monocytaire dans un prélèvement de tissu. En particulier, la présente invention concerne un procédé de quantification de la population de cellules d'origine monocytaire dans un prélèvement de tissu obtenu auprès d'un sujet comprenant la détermination du niveau d'expression d'au moins un gène sélectionné dans le groupe constitué de CSF1R, ADAP2, RASSF4, FPR3, TFEC, PLA2G7 et KYNU.
PCT/EP2016/073055 2015-09-29 2016-09-28 Procédés de quantification de la population de cellules d'origine monocytaire dans un prélèvement de tissu WO2017055324A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15306522 2015-09-29
EPEP15306522.2 2015-09-29
EPEP16305888.6 2016-07-12
EP16305888 2016-07-12

Publications (1)

Publication Number Publication Date
WO2017055324A1 true WO2017055324A1 (fr) 2017-04-06

Family

ID=57047214

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/073055 WO2017055324A1 (fr) 2015-09-29 2016-09-28 Procédés de quantification de la population de cellules d'origine monocytaire dans un prélèvement de tissu

Country Status (1)

Country Link
WO (1) WO2017055324A1 (fr)

Citations (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4774339A (en) 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
US4888278A (en) 1985-10-22 1989-12-19 University Of Massachusetts Medical Center In-situ hybridization to detect nucleic acid sequences in morphologically intact cells
US5132432A (en) 1989-09-22 1992-07-21 Molecular Probes, Inc. Chemically reactive pyrenyloxy sulfonic acid dyes
US5187288A (en) 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
US5248782A (en) 1990-12-18 1993-09-28 Molecular Probes, Inc. Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5262357A (en) 1991-11-22 1993-11-16 The Regents Of The University Of California Low temperature thin films formed from nanocrystal precursors
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5338854A (en) 1991-02-13 1994-08-16 Molecular Probes, Inc. Fluorescent fatty acids derived from dipyrrometheneboron difluoride dyes
US5427932A (en) 1991-04-09 1995-06-27 Reagents Of The University Of California Repeat sequence chromosome specific nucleic acid probes and methods of preparing and using
US5433896A (en) 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5447841A (en) 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US5472842A (en) 1993-10-06 1995-12-05 The Regents Of The University Of California Detection of amplified or deleted chromosomal regions
US5505928A (en) 1991-11-22 1996-04-09 The Regents Of University Of California Preparation of III-V semiconductor nanocrystals
US5571018A (en) 1994-11-23 1996-11-05 Motorola, Inc. Arrangement for simulating indirect fire in combat training
US5618829A (en) 1993-01-28 1997-04-08 Mitsubishi Chemical Corporation Tyrosine kinase inhibitors and benzoylacrylamide derivatives
US5639757A (en) 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
US5690807A (en) 1995-08-03 1997-11-25 Massachusetts Institute Of Technology Method for producing semiconductor particles
US5696157A (en) 1996-11-15 1997-12-09 Molecular Probes, Inc. Sulfonated derivatives of 7-aminocoumarin
US5728868A (en) 1993-07-15 1998-03-17 Cancer Research Campaign Technology Limited Prodrugs of protein tyrosine kinase inhibitors
US5800996A (en) 1996-05-03 1998-09-01 The Perkin Elmer Corporation Energy transfer dyes with enchanced fluorescence
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
WO1998045331A2 (fr) 1997-04-07 1998-10-15 Genentech, Inc. Anticorps anti-vegf
US5830912A (en) 1996-11-15 1998-11-03 Molecular Probes, Inc. Derivatives of 6,8-difluoro-7-hydroxycoumarin
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5866366A (en) 1997-07-01 1999-02-02 Smithkline Beecham Corporation gidB
WO1999026299A1 (fr) 1997-11-13 1999-05-27 Massachusetts Institute Of Technology Materiaux chromo-selectifs hautement luminescents
US5990479A (en) 1997-11-25 1999-11-23 Regents Of The University Of California Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6048616A (en) 1993-04-21 2000-04-11 Philips Electronics N.A. Corp. Encapsulated quantum sized doped semiconductor particles and method of manufacturing same
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
US6114038A (en) 1998-11-10 2000-09-05 Biocrystal Ltd. Functionalized nanocrystals and their use in detection systems
US6127374A (en) 1997-07-29 2000-10-03 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases
US6130101A (en) 1997-09-23 2000-10-10 Molecular Probes, Inc. Sulfonated xanthene derivatives
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US6207392B1 (en) 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6225198B1 (en) 2000-02-04 2001-05-01 The Regents Of The University Of California Process for forming shaped group II-VI semiconductor nanocrystals, and product formed using process
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6274323B1 (en) 1999-05-07 2001-08-14 Quantum Dot Corporation Method of detecting an analyte in a sample using semiconductor nanocrystals as a detectable label
US6280929B1 (en) 1986-01-16 2001-08-28 The Regents Of The University Of California Method of detecting genetic translocations identified with chromosomal abnormalities
US6306874B1 (en) 1999-10-19 2001-10-23 Merck & Co., Inc. Tyrosine kinase inhibitors
US6306736B1 (en) 2000-02-04 2001-10-23 The Regents Of The University Of California Process for forming shaped group III-V semiconductor nanocrystals, and product formed using process
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6316444B1 (en) 1999-06-30 2001-11-13 Merck & Co., Inc. SRC kinase inhibitor compounds
US6329380B1 (en) 1999-06-30 2001-12-11 Merck & Co., Inc. SRC kinase inhibitor compounds
US6344459B1 (en) 1996-04-12 2002-02-05 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
US6479512B1 (en) 1999-10-19 2002-11-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6498165B1 (en) 1999-06-30 2002-12-24 Merck & Co., Inc. Src kinase inhibitor compounds
US6500622B2 (en) 2000-03-22 2002-12-31 Quantum Dot Corporation Methods of using semiconductor nanocrystals in bead-based nucleic acid assays
WO2003042402A2 (fr) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents modulant l'activite de cellules immunes et procedes d'utilisation associes
US6586424B2 (en) 1999-09-10 2003-07-01 Merck & Co., Inc. Tyrosine kinase inhibitors
US6602671B1 (en) 1998-09-18 2003-08-05 Massachusetts Institute Of Technology Semiconductor nanocrystals for inventory control
US20030148295A1 (en) * 2001-03-20 2003-08-07 Wan Jackson Shek-Lam Expression profiles and methods of use
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US20030190317A1 (en) 1997-04-07 2003-10-09 Genentech, Inc. Anti-VEGF antibodies
US6649138B2 (en) 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
WO2003106706A2 (fr) * 2002-06-14 2003-12-24 Millenium Biologix Ag Identification de genes marqueurs specifiques de tissus et cellules, et utilisation y relative
US6670113B2 (en) 2001-03-30 2003-12-30 Nanoprobes Enzymatic deposition and alteration of metals
US6682596B2 (en) 2000-12-28 2004-01-27 Quantum Dot Corporation Flow synthesis of quantum dot nanocrystals
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US6689338B2 (en) 2000-06-01 2004-02-10 The Board Of Regents For Oklahoma State University Bioconjugates of nanoparticles as radiopharmaceuticals
US6709929B2 (en) 2001-06-25 2004-03-23 North Carolina State University Methods of forming nano-scale electronic and optoelectronic devices using non-photolithographically defined nano-channel templates
US6716979B2 (en) 2000-08-04 2004-04-06 Molecular Probes, Inc. Derivatives of 1,2-dihydro-7-hydroxyquinolines containing fused rings
US6740665B1 (en) 1999-02-10 2004-05-25 Ramachandran Murali Tyrosine kinase inhibitors and methods of using the same
US6794393B1 (en) 1999-10-19 2004-09-21 Merck & Co., Inc. Tyrosine kinase inhibitors
US6815064B2 (en) 2001-07-20 2004-11-09 Quantum Dot Corporation Luminescent nanoparticles and methods for their preparation
WO2004106925A2 (fr) * 2003-03-03 2004-12-09 Nagaoka & Co.Ltd. Procedes et appareil utilises pour la detection et la quantification de divers types de cellules et utilisation d'un bio-disque optique pour leur mise en oeuvre
US20040265922A1 (en) 2003-06-24 2004-12-30 Ventana Medical Systems, Inc. Enzyme-catalyzed metal deposition for the enhanced in situ detection of immunohistochemical epitopes and nucleic acid sequences
US6855202B2 (en) 2001-11-30 2005-02-15 The Regents Of The University Of California Shaped nanocrystal particles and methods for making the same
US6875767B2 (en) 2001-06-22 2005-04-05 Merck & Co., Inc. (5-cyano-2-thiazolyl)amino-4-pyridine tyrosine kinase inhibitors
US20050100976A1 (en) 2003-06-24 2005-05-12 Christopher Bieniarz Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest
US6927293B2 (en) 2001-08-30 2005-08-09 Merck & Co., Inc. Tyrosine kinase inhibitors
US6942970B2 (en) 2000-09-14 2005-09-13 Zymed Laboratories, Inc. Identifying subjects suitable for topoisomerase II inhibitor treatment
US6958340B2 (en) 2001-08-01 2005-10-25 Merck & Co., Inc. Tyrosine kinase inhibitors
US6984720B1 (en) 1999-08-24 2006-01-10 Medarex, Inc. Human CTLA-4 antibodies
US20060246523A1 (en) 2005-04-28 2006-11-02 Christopher Bieniarz Antibody conjugates
US20060246524A1 (en) 2005-04-28 2006-11-02 Christina Bauer Nanoparticle conjugates
US20070117153A1 (en) 2005-11-23 2007-05-24 Christopher Bieniarz Molecular conjugate
WO2007076129A2 (fr) 2005-12-23 2007-07-05 Nanostring Technologies, Inc. Nanorapporteurs et procedes de production et d'utilisation de ceux-ci
WO2007076132A2 (fr) 2005-12-23 2007-07-05 Nanostring Technologies, Inc. Compositions comprenant des macromolecules immobilisees et orientees et leurs procedes de preparation
US20070254295A1 (en) 2006-03-17 2007-11-01 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
WO2008124847A2 (fr) 2007-04-10 2008-10-16 Nanostring Technologies, Inc. Procédés et systèmes informatiques pour identifier des séquences spécifiques d'une cible afin de les utiliser dans des nanoreporteurs
WO2008156712A1 (fr) 2007-06-18 2008-12-24 N. V. Organon Anticorps dirigés contre le récepteur humain de mort programmée pd-1
US7488802B2 (en) 2002-12-23 2009-02-10 Wyeth Antibodies against PD-1
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2010019826A1 (fr) 2008-08-14 2010-02-18 Nanostring Technologies, Inc Nanoreporteurs stables
WO2010036959A2 (fr) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Anticorps anti-pd-1, pd-l1, et pd-l2 humains et leurs utilisations
WO2010089411A2 (fr) 2009-02-09 2010-08-12 Universite De La Mediterranee Anticorps pd-1 et anticorps pd-l1 et leurs utilisations
US7943743B2 (en) 2005-07-01 2011-05-17 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
WO2011066342A2 (fr) 2009-11-24 2011-06-03 Amplimmune, Inc. Inhibition simultanée de pd-l1/pd-l2
WO2011082400A2 (fr) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulateurs du récepteur immunosuppresseur pd-1 et procédés d'utilisation de ceux-ci
US8008449B2 (en) 2005-05-09 2011-08-30 Medarex, Inc. Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
WO2011159877A2 (fr) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Anticorps di-spécifiques anti-tim-3 et pd-1 pour immunothérapie dans des états pathologiques immuns chroniques
WO2011161699A2 (fr) 2010-06-25 2011-12-29 Aurigene Discovery Technologies Limited Composés modulateurs de l'immunosuppression
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
US8217149B2 (en) 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture

Patent Citations (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4888278A (en) 1985-10-22 1989-12-19 University Of Massachusetts Medical Center In-situ hybridization to detect nucleic acid sequences in morphologically intact cells
US6280929B1 (en) 1986-01-16 2001-08-28 The Regents Of The University Of California Method of detecting genetic translocations identified with chromosomal abnormalities
US5447841A (en) 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US4774339A (en) 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
US5132432A (en) 1989-09-22 1992-07-21 Molecular Probes, Inc. Chemically reactive pyrenyloxy sulfonic acid dyes
US5248782A (en) 1990-12-18 1993-09-28 Molecular Probes, Inc. Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5338854A (en) 1991-02-13 1994-08-16 Molecular Probes, Inc. Fluorescent fatty acids derived from dipyrrometheneboron difluoride dyes
US5427932A (en) 1991-04-09 1995-06-27 Reagents Of The University Of California Repeat sequence chromosome specific nucleic acid probes and methods of preparing and using
US5187288A (en) 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
US5451663A (en) 1991-11-01 1995-09-19 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5505928A (en) 1991-11-22 1996-04-09 The Regents Of University Of California Preparation of III-V semiconductor nanocrystals
US5262357A (en) 1991-11-22 1993-11-16 The Regents Of The University Of California Low temperature thin films formed from nanocrystal precursors
US5618829A (en) 1993-01-28 1997-04-08 Mitsubishi Chemical Corporation Tyrosine kinase inhibitors and benzoylacrylamide derivatives
US6048616A (en) 1993-04-21 2000-04-11 Philips Electronics N.A. Corp. Encapsulated quantum sized doped semiconductor particles and method of manufacturing same
US5728868A (en) 1993-07-15 1998-03-17 Cancer Research Campaign Technology Limited Prodrugs of protein tyrosine kinase inhibitors
US5472842A (en) 1993-10-06 1995-12-05 The Regents Of The University Of California Detection of amplified or deleted chromosomal regions
US5433896A (en) 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5571018A (en) 1994-11-23 1996-11-05 Motorola, Inc. Arrangement for simulating indirect fire in combat training
US5639757A (en) 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5690807A (en) 1995-08-03 1997-11-25 Massachusetts Institute Of Technology Method for producing semiconductor particles
US6344459B1 (en) 1996-04-12 2002-02-05 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US5800996A (en) 1996-05-03 1998-09-01 The Perkin Elmer Corporation Energy transfer dyes with enchanced fluorescence
US5830912A (en) 1996-11-15 1998-11-03 Molecular Probes, Inc. Derivatives of 6,8-difluoro-7-hydroxycoumarin
US5696157A (en) 1996-11-15 1997-12-09 Molecular Probes, Inc. Sulfonated derivatives of 7-aminocoumarin
US20030190317A1 (en) 1997-04-07 2003-10-09 Genentech, Inc. Anti-VEGF antibodies
WO1998045331A2 (fr) 1997-04-07 1998-10-15 Genentech, Inc. Anticorps anti-vegf
US5866366A (en) 1997-07-01 1999-02-02 Smithkline Beecham Corporation gidB
US6127374A (en) 1997-07-29 2000-10-03 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases
US6562818B1 (en) 1997-07-29 2003-05-13 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases
US6130101A (en) 1997-09-23 2000-10-10 Molecular Probes, Inc. Sulfonated xanthene derivatives
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
WO1999026299A1 (fr) 1997-11-13 1999-05-27 Massachusetts Institute Of Technology Materiaux chromo-selectifs hautement luminescents
US5990479A (en) 1997-11-25 1999-11-23 Regents Of The University Of California Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6927069B2 (en) 1997-11-25 2005-08-09 The Regents Of The University Of California Organo luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6207392B1 (en) 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6602671B1 (en) 1998-09-18 2003-08-05 Massachusetts Institute Of Technology Semiconductor nanocrystals for inventory control
US6114038A (en) 1998-11-10 2000-09-05 Biocrystal Ltd. Functionalized nanocrystals and their use in detection systems
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US6740665B1 (en) 1999-02-10 2004-05-25 Ramachandran Murali Tyrosine kinase inhibitors and methods of using the same
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6544988B1 (en) 1999-03-11 2003-04-08 Merck & Co., Inc. Tyrosine kinase inhibitors
US6274323B1 (en) 1999-05-07 2001-08-14 Quantum Dot Corporation Method of detecting an analyte in a sample using semiconductor nanocrystals as a detectable label
US6316444B1 (en) 1999-06-30 2001-11-13 Merck & Co., Inc. SRC kinase inhibitor compounds
US6329380B1 (en) 1999-06-30 2001-12-11 Merck & Co., Inc. SRC kinase inhibitor compounds
US6498165B1 (en) 1999-06-30 2002-12-24 Merck & Co., Inc. Src kinase inhibitor compounds
US6984720B1 (en) 1999-08-24 2006-01-10 Medarex, Inc. Human CTLA-4 antibodies
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US6586424B2 (en) 1999-09-10 2003-07-01 Merck & Co., Inc. Tyrosine kinase inhibitors
US6586423B2 (en) 1999-09-10 2003-07-01 Merck & Co., Inc. Tyrosine kinase inhibitors
US6306874B1 (en) 1999-10-19 2001-10-23 Merck & Co., Inc. Tyrosine kinase inhibitors
US6479512B1 (en) 1999-10-19 2002-11-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6794393B1 (en) 1999-10-19 2004-09-21 Merck & Co., Inc. Tyrosine kinase inhibitors
US6225198B1 (en) 2000-02-04 2001-05-01 The Regents Of The University Of California Process for forming shaped group II-VI semiconductor nanocrystals, and product formed using process
US6306736B1 (en) 2000-02-04 2001-10-23 The Regents Of The University Of California Process for forming shaped group III-V semiconductor nanocrystals, and product formed using process
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
US6500622B2 (en) 2000-03-22 2002-12-31 Quantum Dot Corporation Methods of using semiconductor nanocrystals in bead-based nucleic acid assays
US20030165951A1 (en) 2000-03-22 2003-09-04 Quantum Dot Corporation Methods of using semiconductor nanocrystals in bead-based nucleic acid assays
US6689338B2 (en) 2000-06-01 2004-02-10 The Board Of Regents For Oklahoma State University Bioconjugates of nanoparticles as radiopharmaceuticals
US6716979B2 (en) 2000-08-04 2004-04-06 Molecular Probes, Inc. Derivatives of 1,2-dihydro-7-hydroxyquinolines containing fused rings
US6942970B2 (en) 2000-09-14 2005-09-13 Zymed Laboratories, Inc. Identifying subjects suitable for topoisomerase II inhibitor treatment
US6649138B2 (en) 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
US6682596B2 (en) 2000-12-28 2004-01-27 Quantum Dot Corporation Flow synthesis of quantum dot nanocrystals
US20030148295A1 (en) * 2001-03-20 2003-08-07 Wan Jackson Shek-Lam Expression profiles and methods of use
US6670113B2 (en) 2001-03-30 2003-12-30 Nanoprobes Enzymatic deposition and alteration of metals
US6875767B2 (en) 2001-06-22 2005-04-05 Merck & Co., Inc. (5-cyano-2-thiazolyl)amino-4-pyridine tyrosine kinase inhibitors
US6914256B2 (en) 2001-06-25 2005-07-05 North Carolina State University Optoelectronic devices having arrays of quantum-dot compound semiconductor superlattices therein
US6709929B2 (en) 2001-06-25 2004-03-23 North Carolina State University Methods of forming nano-scale electronic and optoelectronic devices using non-photolithographically defined nano-channel templates
US6815064B2 (en) 2001-07-20 2004-11-09 Quantum Dot Corporation Luminescent nanoparticles and methods for their preparation
US6958340B2 (en) 2001-08-01 2005-10-25 Merck & Co., Inc. Tyrosine kinase inhibitors
US6927293B2 (en) 2001-08-30 2005-08-09 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003042402A2 (fr) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents modulant l'activite de cellules immunes et procedes d'utilisation associes
US6855202B2 (en) 2001-11-30 2005-02-15 The Regents Of The University Of California Shaped nanocrystal particles and methods for making the same
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
WO2003106706A2 (fr) * 2002-06-14 2003-12-24 Millenium Biologix Ag Identification de genes marqueurs specifiques de tissus et cellules, et utilisation y relative
US7488802B2 (en) 2002-12-23 2009-02-10 Wyeth Antibodies against PD-1
WO2004106925A2 (fr) * 2003-03-03 2004-12-09 Nagaoka & Co.Ltd. Procedes et appareil utilises pour la detection et la quantification de divers types de cellules et utilisation d'un bio-disque optique pour leur mise en oeuvre
US20040265922A1 (en) 2003-06-24 2004-12-30 Ventana Medical Systems, Inc. Enzyme-catalyzed metal deposition for the enhanced in situ detection of immunohistochemical epitopes and nucleic acid sequences
US20050100976A1 (en) 2003-06-24 2005-05-12 Christopher Bieniarz Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest
WO2005003777A2 (fr) 2003-06-24 2005-01-13 Ventana Medical Systems, Inc. Depot de metal catalyse par une enzyme pour la detection in situ amelioree d'epitopes immunohistochimiques et de sequences d'acides nucleiques
US20060246523A1 (en) 2005-04-28 2006-11-02 Christopher Bieniarz Antibody conjugates
US20060246524A1 (en) 2005-04-28 2006-11-02 Christina Bauer Nanoparticle conjugates
US8008449B2 (en) 2005-05-09 2011-08-30 Medarex, Inc. Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
US7943743B2 (en) 2005-07-01 2011-05-17 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
US20070117153A1 (en) 2005-11-23 2007-05-24 Christopher Bieniarz Molecular conjugate
WO2007076129A2 (fr) 2005-12-23 2007-07-05 Nanostring Technologies, Inc. Nanorapporteurs et procedes de production et d'utilisation de ceux-ci
US20100015607A1 (en) 2005-12-23 2010-01-21 Nanostring Technologies, Inc. Nanoreporters and methods of manufacturing and use thereof
WO2007076132A2 (fr) 2005-12-23 2007-07-05 Nanostring Technologies, Inc. Compositions comprenant des macromolecules immobilisees et orientees et leurs procedes de preparation
US20100261026A1 (en) 2005-12-23 2010-10-14 Nanostring Technologies, Inc. Compositions comprising oriented, immobilized macromolecules and methods for their preparation
US20070254295A1 (en) 2006-03-17 2007-11-01 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
WO2008124847A2 (fr) 2007-04-10 2008-10-16 Nanostring Technologies, Inc. Procédés et systèmes informatiques pour identifier des séquences spécifiques d'une cible afin de les utiliser dans des nanoreporteurs
US8415102B2 (en) 2007-04-10 2013-04-09 Nanostring Technologies, Inc. Methods and computer systems for identifying target-specific sequences for use in nanoreporters
WO2008156712A1 (fr) 2007-06-18 2008-12-24 N. V. Organon Anticorps dirigés contre le récepteur humain de mort programmée pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
US20100047924A1 (en) 2008-08-14 2010-02-25 Nanostring Technologies, Inc. Stable nanoreporters
WO2010019826A1 (fr) 2008-08-14 2010-02-18 Nanostring Technologies, Inc Nanoreporteurs stables
WO2010036959A2 (fr) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Anticorps anti-pd-1, pd-l1, et pd-l2 humains et leurs utilisations
US8217149B2 (en) 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture
WO2010089411A2 (fr) 2009-02-09 2010-08-12 Universite De La Mediterranee Anticorps pd-1 et anticorps pd-l1 et leurs utilisations
WO2011066342A2 (fr) 2009-11-24 2011-06-03 Amplimmune, Inc. Inhibition simultanée de pd-l1/pd-l2
WO2011082400A2 (fr) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulateurs du récepteur immunosuppresseur pd-1 et procédés d'utilisation de ceux-ci
WO2011159877A2 (fr) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Anticorps di-spécifiques anti-tim-3 et pd-1 pour immunothérapie dans des états pathologiques immuns chroniques
WO2011161699A2 (fr) 2010-06-25 2011-12-29 Aurigene Discovery Technologies Limited Composés modulateurs de l'immunosuppression

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
AGNEW CHEM INTL. ED. ENGL., vol. 33, 1994, pages 183 - 186
BRIGNONE ET AL., J. IMMUNOL., vol. 179, 2007, pages 4202 - 4211
BRUCHEZ ET AL., SCIENCE, vol. 281, 1998, pages 2013 - 2016
CHAN ET AL., SCIENCE, vol. 281, 1998, pages 2016 - 2018
DU X ET AL: "Genomic profiles for human peripheral blood T cells, B cells, natural killer cells, monocytes, and polymorphonuclear cells: Comparisons to ischemic stroke, migraine, and Tourette syndrome", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 87, no. 6, 1 June 2006 (2006-06-01), pages 693 - 703, XP024929515, ISSN: 0888-7543, [retrieved on 20060601], DOI: 10.1016/J.YGENO.2006.02.003 *
FOURCADE ET AL., J. EXP. MED., vol. 207, 2010, pages 2175 - 2186
GEISS ET AL., NATURE BIOTECHNOLOGY, vol. 26, no. 3, 2008, pages 317 - 325
HEYDUK; HEYDUK, ANALYT. BIOCHEM., vol. 248, 1997, pages 216 - 227
HOHEISEL, NATURE REVIEWS, GENETICS, vol. 7, 2006, pages 200 - 210
J. BIOL. CHEM., vol. 274, 1999, pages 3315 - 3322
L. OESPER ET AL: "Quantifying tumor heterogeneity in whole-genome and whole-exome sequencing data", BIOINFORMATICS., vol. 30, no. 24, 8 October 2014 (2014-10-08), GB, pages 3532 - 3540, XP055249401, ISSN: 1367-4803, DOI: 10.1093/bioinformatics/btu651 *
LICHTER ET AL., PROC. NATL. ACAD. SCI., vol. 85, 1988, pages 9664 - 9668
LOO ET AL., CLIN. CANCER RES., vol. 15, no. 18, July 2012 (2012-07-01), pages 3834
NEIL A MABBOTT ET AL: "An expression atlas of human primary cells: inference of gene function from coexpression networks", BMC GENOMICS, BIOMED CENTRAL LTD, LONDON, UK, vol. 14, no. 1, 20 September 2013 (2013-09-20), pages 632, XP021163126, ISSN: 1471-2164, DOI: 10.1186/1471-2164-14-632 *
NICHOLAS P. RESTIFO; MARK E. DUDLEY; STEVEN A. ROSENBERG: "Adoptive immunotherapy for cancer: harnessing the T cell response", NATURE REVIEWS IMMUNOLOGY, vol. 12, April 2012 (2012-04-01), XP055034896, DOI: doi:10.1038/nri3191
PARDOLL, NATURE REVIEWS CANCER, vol. 12, 2012, pages 252 - 264
PINKEL ET AL., PROC. NATL. ACAD. SCI., vol. 85, 1988, pages 9138 - 9142
PIRLKEL ET AL., PROC. NATL. ACAD. SCI., vol. 83, 1986, pages 2934 - 2938
SAKUISHI ET AL., J. EXP. MED., vol. 207, 2010, pages 2187 - 2194
TANNER ET AL., AM..1. PATHOL., vol. 157, 2000, pages 1467 - 1472

Similar Documents

Publication Publication Date Title
US20220259665A1 (en) Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes
EP3455631B1 (fr) Procédés pour la classification de patients atteints d'un cancer solide
US20200299784A1 (en) Methods and kits for screening patients with cancer
US11473150B2 (en) Methods for the detection and treatment of classes of hepatocellular carcinoma responsive to immunotherapy
AU2014232794A1 (en) Dendritic cell response gene expression, compositions of matters and methods of use thereof
US20230113705A1 (en) Methods for diagnosing, prognosing and managing treatment of breast cancer
Miyawaki et al. Lymphoma Microenvironment in DLBCL and PTCL-NOS: the key to uncovering heterogeneity and the potential for stratification
WO2018011166A2 (fr) Procédés de quantification de la population de cellules dendritiques myéloïdes dans un échantillon de tissu
WO2017055327A1 (fr) Procédés de quantification de la population de cellules endothéliales dans un échantillon de tissu
WO2017055322A1 (fr) Procédés de quantification de la population de neutrophiles dans un prélèvement de tissu
WO2017055319A1 (fr) Procédés de quantification de la population de cellules b dans un prélèvement de tissu
WO2017055321A1 (fr) Procédés de quantification de la population de fibroblastes dans un prélèvement de tissu
WO2017055320A1 (fr) Procédé de quantification de la population de lymphocytes cytotoxiques dans un prélèvement de tissu
WO2017055324A1 (fr) Procédés de quantification de la population de cellules d'origine monocytaire dans un prélèvement de tissu
WO2017055326A1 (fr) Procédés de quantification de la population de cellules dendritiques myéloïdes dans un prélèvement de tissu
WO2017055325A1 (fr) Procédés de quantification de la population de cellules nk dans un prélèvement de tissu
US20200095643A1 (en) Tim-3 for assessing the severity of cancer
WO2019043138A1 (fr) Procédé de prédiction de l'issue d'un cancer
US11881286B2 (en) CD8+ t cell based immunosuppressive tumor microenvironment detection method
Ramdani et al. Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors
CA3157889A1 (fr) Procedes de diagnostic d'adenocarcinomes du type intestinal nasal
Yang The Molecular Determinants of Response to Immune Checkpoint Therapy in Solid Tumors
Bird et al. Cancer Immunotherapy Biomarkers of Response and Toxicity; current limitations and future promise
Sivakumar et al. Single-cell immune multi-omics and repertoire analyses in pancreatic ductal adenocarcinoma reveal differential immunosuppressive mechanisms within different tumour microenvironments

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16775197

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16775197

Country of ref document: EP

Kind code of ref document: A1